Dimethyl Sulfoxide
Apexbio Technology LLC Amantadine HCl 665-66-7 10mM (in 1mL DMSO)
Amantadine Hydrochloride a dopamine receptor agonist is primarily employed as a research tool in neuroscience and antiviral studies It exerts its antiparkinsonian effects by promoting dopamine release and inhibiting dopamine reuptake consequently enhancing dopaminergic neurotransmission As an antiviral agent amantadine hydrochloride inhibits influenza A virus replication through blockade of the viral matrix protein M2 ion channel In cell-based assays amantadine hydrochloride demonstrates inhibitory activity against influenza A viruses with reported IC50 values typically ranging between 0 3 to 1 5 M depending on assay conditions and viral strains Researchers commonly utilize this compound to investigate neurological pathways associated with Parkinson s disease viral infection mechanisms and drug resistance phenomena
Apexbio Technology LLC Z-FA-FMK 105637-38-5;197855-65-5 10mM (in 1mL DMSO)
Z-FA-FMK is a peptidyl fluoromethyl ketone inhibitor targeting cysteine proteases specifically cathepsins such as cathepsin B and certain caspases It does not require a P1 aspartate residue for inhibition Mechanistically Z-FA-FMK suppresses the enzyme activity of effector caspases (including caspases-2 -3 -6 and -7) but shows minimal impact on initiator caspases (caspase-8 and caspase-10) and only partial attenuation of caspase-9 activity As a negative control inhibitor Z-FA-FMK is regularly applied in apoptosis research to differentiate specific caspase-dependent signaling pathways and to assess the role of cathepsins and caspases in biological contexts such as cell death mechanisms and related pathways
Apexbio Technology LLC Famprofazone 10mM (in 1mL DMSO)
A8431 is a small molecule that functions as a selective inhibitor of autophagy a conserved cellular pathway responsible for the lysosome-mediated degradation of intracellular components Acting primarily through interference with autophagosome formation or lysosomal fusion A8431 disrupts autophagic flux and thus influences cellular homeostasis and survival pathways It is widely utilized in biomedical research to dissect autophagy-mediated cellular mechanisms and has relevance in studies of cancer biology neurodegeneration and metabolic disorders where autophagy regulation is implicated
Apexbio Technology LLC GSK1838705A 1116235-97-2 10mM (in 1mL DMSO)
GSK1838705A (CAS 1116235-97-2) is a small molecule inhibitor targeting the kinase activity of insulin-like growth factor-1 receptor (IGF-1R) insulin receptor and anaplastic lymphoma kinase (ALK) It exhibits potent inhibition with IC50 values of 2 0 nM for IGF-1R 1 6 nM for insulin receptor and 0 5 nM for ALK In preclinical research GSK1838705A suppresses proliferation of hematologic malignancy-derived tumor cells including multiple myeloma and Ewing sarcoma lines and inhibits tumor xenograft growth in vivo Additionally despite targeting the insulin receptor it minimally affects glucose homeostasis at effective doses Due to its multi-target kinase inhibitory profile GSK1838705A serves as a promising tool for cancer biology research
Apexbio Technology LLC Salubrinal 405060-95-9 10mM (in 1mL DMSO)
Salubrinal is a cell-permeable inhibitor of eukaryotic translation initiation factor 2 alpha (eIF2 ) dephosphorylation exhibiting an IC50 of approximately 15 M It prevents phosphatase complexes from removing phosphate groups from eIF2 thus maintaining its phosphorylated state and modulating protein synthesis during cellular stress responses Salubrinal is utilized experimentally in vitro to investigate apoptotic mechanisms related to endoplasmic reticulum (ER) stress For instance it provides cytoprotection against ER stress-induced apoptosis triggered by protein glycosylation inhibitors or ER-Golgi trafficking inhibitors In vivo murine models employ salubrinal to explore cellular processes underlying oxidative stress and nephrotoxicity induced by chemotherapeutic treatments through modulation of ER stress-associated apoptosis signaling pathways Currently no clinical trials involving salubrinal have been reported
Apexbio Technology LLC Pacritinib (SB1518) 937272-79-2 10mM (in 1mL DMSO)
Pacritinib (SB1518) is a small molecule inhibitor targeting Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3 (FLT3) with IC50 values of 23 nM for wild-type JAK2 19 nM for JAK2V617F and 22 nM for FLT3 It inhibits phosphorylation of downstream effectors such as STAT5 and STAT3 mediated by JAK2 in Ba/F3 cells as well as phosphorylation of FLT3 and STAT5 in MV4-11 cells Pacritinib demonstrates good microsomal stability selectivity limited inhibitory activity toward CYP3A4 favorable permeability in cell permeability assays and oral bioavailability In preclinical studies treatment with pacritinib in Ba/F3-JAK2V617F murine allograft and MV4-11 xenograft models reduces disease progression and enhances survival These properties make pacritinib suitable for research concerning hematologic malignancies involving dysregulated JAK2 or FLT3 signaling pathways
Apexbio Technology LLC CGP 57380 522629-08-9 10mM (in 1mL DMSO)
CGP 57380 (CAS 522629-08-9) is a specific and selective inhibitor targeting the serine/threonine kinase MNK1 an enzyme implicated in translation regulation via phosphorylation of the eukaryotic initiation factor 4E (eIF4E) It inhibits MNK1 activity in vitro with an IC50 of approximately 2 2 M CGP 57380 suppresses stimulus-induced phosphorylation of eIF4E in various cellular contexts including 293 cells vascular smooth muscle cells and macrophages reducing translation of mRNAs encoding proinflammatory mediators such as TNF- IL-6 and monocyte chemoattractant protein-1 (MCP-1) Hence CGP 57380 is valuable for investigating MNK1-mediated translational control in inflammation and cell signaling
Apexbio Technology LLC U-73122 112648-68-7 10mM (in 1mL DMSO)
U-73122 (CAS 112648-68-7) is a phospholipase C (PLC) inhibitor utilized in biomedical research By selectively targeting PLC an enzyme responsible for hydrolyzing phosphatidylinositol 4 5-bisphosphate into intracellular messengers diacylglycerol and inositol-triphosphate U-73122 attenuates downstream signaling events such as protein kinase C activation and intracellular calcium release In vitro U-73122 inhibits recombinant human PLC- 2 with an IC50 of approximately 6 M while minimally affecting PLC- 1 3 and 4 isoforms In animal models U-73122 demonstrates anti-inflammatory properties reducing carrageenan-induced rat paw edema and TPA-induced mouse ear edema
Sigma Aldrich Fine Chemicals Biosciences Dimethyl sulfoxide | 67-68-5 | MFCD00002089 | 6 x 1 L
Dimethyl sulfoxide | Purity: ≥99.5% | Mol Wt: 78.13 | 67-68-5 | MFCD00002089 | 6 x 1 L
Apexbio Technology LLC Tolcapone 134308-13-7 10mM (in 1mL DMSO)
Tolcapone (CAS 134308-13-7) is an orally bioavailable reversible small-molecule inhibitor targeting catechol-O-methyltransferase (COMT) Acting through competitive inhibition tolcapone structurally incorporates a catechol moiety with electron-withdrawing substituents facilitating anionic formation that binds potently to COMT s catalytic site (reported IC50 of approximately 36 nM in rat liver assays) By competitively occupying this active site tolcapone prevents the enzymatic methylation of endogenous catechols such as levodopa thus prolonging levodopa s bioavailability Tolcapone is primarily investigated as adjunctive therapeutic agent in Parkinson s disease research enabling reduced levodopa dosage while enhancing symptomatic control
Apexbio Technology LLC Halcinonide 3093-35-4 10mM (in 1mL DMSO)
Halcinonide (CAS 3093-35-4) is a potent synthetic corticosteroid widely utilized in biomedical research as a topical anti-inflammatory agent Mechanistically halcinonide exerts biological effects primarily through activation of glucocorticoid receptor pathways subsequently modulating gene transcription and suppressing the release of inflammatory mediators Owing to its robust corticosteroid receptor agonism and pronounced anti-inflammatory properties this compound frequently supports investigations into inflammatory dermatological conditions and glucocorticoid signaling pathways
Apexbio Technology LLC Dacomitinib (PF299804, PF299) 1110813-31-4 10mM (in 1mL DMSO)
Dacomitinib (PF299804 CAS 1110813-31-4) is an irreversible pan-HER small-molecule inhibitor that targets the epidermal growth factor receptor (EGFR/ErbB-1) ERBB2 (HER2) and ERBB4 (HER4) It acts by covalently binding EGFR family tyrosine kinases inhibiting downstream signaling through phospho-HER family proteins AKT and ERK Dacomitinib shows activity in vitro inducing G0/G1 cell cycle arrest and apoptosis and suppresses proliferation in trastuzumab- or lapatinib-resistant HER2-amplified breast cancer cell lines In vivo studies demonstrate antitumor effects in EGFR-mutant (e g T790M) gefitinib-resistant lung cancer xenografts making it relevant for non-small cell lung cancer research
Apexbio Technology LLC K02288 1431985-92-0 10mM (in 1mL DMSO)
K02288 (CAS 1431985-92-0) is a highly selective small molecule inhibitor targeting activin receptor-like kinase 2 (ALK2) a type I receptor involved in BMP signaling Structurally classified as a 2-aminopyridine derivative K02288 demonstrates strong potency against ALK2 (IC50 1 1 nM) It exhibits selectivity across the ALK receptor family showing lower activity on ALK3 ALK6 and minimal inhibition against ALK4-5 In cell-based assays using C2C12 cells treated with BMP ligands K02288 dose-dependently reduces Smad phosphorylation It has utility in research elucidating ALK2-mediated signaling pathways and developmental processes exemplified by inducing dorsalized phenotypes in zebrafish embryos
Apexbio Technology LLC Baricitinib (LY3009104, INCB028050) 1187594-09-7 10mM (in 1mL DMSO)
Baricitinib (LY3009104 INCB028050 CAS 1187594-09-7) is an orally bioavailable ATP-competitive inhibitor targeting Janus kinases JAK1 and JAK2 It also exhibits moderate inhibition of TYK2 and weaker inhibition against JAK3 In biochemical assays baricitinib inhibits JAK1 and JAK2 with IC50 values of 5 9 nM and 5 7 nM respectively At concentrations below 50 nM baricitinib suppresses intracellular signaling mediated by several pro-inflammatory cytokines notably IL-6 and IL-23 Due to its mechanistic profile baricitinib is actively explored in inflammatory disease research such as rheumatoid arthritis
Apexbio Technology LLC VER 155008 1134156-31-2 10mM (in 1mL DMSO)
VER 155008 (CAS 1134156-31-2) is a small molecule inhibitor targeting members of the heat shock protein 70 (Hsp70) chaperone family It primarily inhibits Hsp70 by binding within its ATPase domain and suppressing its intrinsic ATPase activity thereby reducing chaperone-mediated cell survival functions VER 155008 demonstrates potent inhibition of Hsp70 (IC50 0 5 M) and exhibits moderate inhibitory action against related chaperones Hsc70 and glucose-regulated protein Grp78 In cancer cell models this compound diminishes cell proliferation and promotes apoptosis suggesting utility as a research tool in studying chaperone-dependent tumor cell survival pathways